IndiumV2, Main, Exploration, bibRecord, 000F38

Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.

Identifieur interne : 000F38 ( Main/Exploration ); précédent : 000F37; suivant : 000F39

Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.

Auteurs : RBID : pubmed:22236704

English descriptors

KwdEn :
- Contrast Media (administration & dosage), Female, Gadolinium DTPA (administration & dosage), Gadolinium DTPA (diagnostic use), Humans, Indium Radioisotopes (diagnostic use), Iopamidol (administration & dosage), Iopamidol (analogs & derivatives), Iopamidol (diagnostic use), Magnetic Resonance Imaging (methods), Male, Neuroendocrine Tumors (diagnosis), Octreotide (analogs & derivatives), Octreotide (diagnostic use), Positron-Emission Tomography (methods), Radiopharmaceuticals (diagnostic use), Reproducibility of Results, Sensitivity and Specificity, Statistics as Topic, Tomography, X-Ray Computed (methods).
MESH :
- chemical , administration & dosage : Contrast Media, Gadolinium DTPA, Iopamidol.
- chemical , analogs & derivatives : Iopamidol, Octreotide.
- chemical , diagnostic use : Gadolinium DTPA, Indium Radioisotopes, Iopamidol, Octreotide, Radiopharmaceuticals.
- diagnosis : Neuroendocrine Tumors.
- methods : Magnetic Resonance Imaging, Positron-Emission Tomography, Tomography, X-Ray Computed.
- Female, Humans, Male, Reproducibility of Results, Sensitivity and Specificity, Statistics as Topic.

Abstract

We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET.

DOI: 10.1016/j.ejrad.2011.11.007
PubMed: 22236704

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000F63
to stream Main, to step Curation: 000F63

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.</title>
<author><name sortKey="Giesel, F L" uniqKey="Giesel F">F L Giesel</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany. f.giesel@dkfz.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kratochwil, C" uniqKey="Kratochwil C">C Kratochwil</name>
</author>
<author><name sortKey="Mehndiratta, A" uniqKey="Mehndiratta A">A Mehndiratta</name>
</author>
<author><name sortKey="Wulfert, S" uniqKey="Wulfert S">S Wulfert</name>
</author>
<author><name sortKey="Moltz, J H" uniqKey="Moltz J">J H Moltz</name>
</author>
<author><name sortKey="Zechmann, C M" uniqKey="Zechmann C">C M Zechmann</name>
</author>
<author><name sortKey="Kauczor, H U" uniqKey="Kauczor H">H U Kauczor</name>
</author>
<author><name sortKey="Haberkorn, U" uniqKey="Haberkorn U">U Haberkorn</name>
</author>
<author><name sortKey="Ley, S" uniqKey="Ley S">S Ley</name>
</author>
</titleStmt>
<publicationStmt><date when="2012">2012</date>
<idno type="doi">10.1016/j.ejrad.2011.11.007</idno>
<idno type="RBID">pubmed:22236704</idno>
<idno type="pmid">22236704</idno>
<idno type="wicri:Area/Main/Corpus">000F63</idno>
<idno type="wicri:Area/Main/Curation">000F63</idno>
<idno type="wicri:Area/Main/Exploration">000F38</idno>
</publicationStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Contrast Media (administration & dosage)</term>
<term>Female</term>
<term>Gadolinium DTPA (administration & dosage)</term>
<term>Gadolinium DTPA (diagnostic use)</term>
<term>Humans</term>
<term>Indium Radioisotopes (diagnostic use)</term>
<term>Iopamidol (administration & dosage)</term>
<term>Iopamidol (analogs & derivatives)</term>
<term>Iopamidol (diagnostic use)</term>
<term>Magnetic Resonance Imaging (methods)</term>
<term>Male</term>
<term>Neuroendocrine Tumors (diagnosis)</term>
<term>Octreotide (analogs & derivatives)</term>
<term>Octreotide (diagnostic use)</term>
<term>Positron-Emission Tomography (methods)</term>
<term>Radiopharmaceuticals (diagnostic use)</term>
<term>Reproducibility of Results</term>
<term>Sensitivity and Specificity</term>
<term>Statistics as Topic</term>
<term>Tomography, X-Ray Computed (methods)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Contrast Media</term>
<term>Gadolinium DTPA</term>
<term>Iopamidol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Iopamidol</term>
<term>Octreotide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Gadolinium DTPA</term>
<term>Indium Radioisotopes</term>
<term>Iopamidol</term>
<term>Octreotide</term>
<term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neuroendocrine Tumors</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetic Resonance Imaging</term>
<term>Positron-Emission Tomography</term>
<term>Tomography, X-Ray Computed</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Reproducibility of Results</term>
<term>Sensitivity and Specificity</term>
<term>Statistics as Topic</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22236704</PMID>
<DateCreated><Year>2012</Year>
<Month>08</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted><Year>2013</Year>
<Month>01</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7727</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>81</Volume>
<Issue>10</Issue>
<PubDate><Year>2012</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>European journal of radiology</Title>
<ISOAbbreviation>Eur J Radiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.</ArticleTitle>
<Pagination><MedlinePgn>2820-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejrad.2011.11.007</ELocationID>
<Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We evaluated the rate of successful characterization of gastroenteropancreatic neuroendocrine tumors (NETs) present with an increased somatostatin receptor, comparing CE-CT with CE-MRI, each in correlation with DOTATOC-PET.</AbstractText>
<AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">8 patients with GEP-NET were imaged using CE-MRI (Gd-EOB-DTPA), CE-CT (Imeron 400) and DOTATOC-PET. Contrast-enhancement of normal liver-tissue and metastasis was quantified with ROI-technique. Tumor delineation was assessed with visual-score in blind-read-analysis by two experienced radiologists.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 40 liver metastases in patients with NETs, all were detected by CE-MRI and the lesion extent could be adequately assessed, whereas CT failed to detect 20% of all metastases. The blind-read-score of CT in arterial and portal phase was median -0.65 and -1.4, respectively, and 2.7 for delayed-MRI. The quantitative ROI-analysis presented an improved contrast-enhancement-ratio with a median of 1.2, 1.6 and 3.3 for CE-CT arterial, portal-phase and delayed-MRI respectively.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Late CE-MRI was superior to CE-CT in providing additionally morphologic characterization and exact lesion extension of hepatic metastases from neuroendocrine tumor detected with DOTATOC-PET. Therefore, late enhanced Gd-EOB-DTPA-MRI seems to be the adequate imaging modality for combination with DOTATOC-PET to provide complementary (macroscopic and molecular) tumor characterization in hepatic metastasized NETs.</AbstractText>
<CopyrightInformation>Copyright © 2011. Published by Elsevier Ireland Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giesel</LastName>
<ForeName>F L</ForeName>
<Initials>FL</Initials>
<Affiliation>Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany. f.giesel@dkfz.de</Affiliation>
</Author>
<Author ValidYN="Y"><LastName>Kratochwil</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mehndiratta</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wulfert</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Moltz</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zechmann</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kauczor</LastName>
<ForeName>H U</ForeName>
<Initials>HU</Initials>
</Author>
<Author ValidYN="Y"><LastName>Haberkorn</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ley</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType>Comparative Study</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>01</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Ireland</Country>
<MedlineTA>Eur J Radiol</MedlineTA>
<NlmUniqueID>8106411</NlmUniqueID>
<ISSNLinking>0720-048X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Contrast Media</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Indium Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Radiopharmaceuticals</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>gadolinium ethoxybenzyl DTPA</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>17E17JBP8L</RegistryNumber>
<NameOfSubstance>iomeprol</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>JR13W81H44</RegistryNumber>
<NameOfSubstance>Iopamidol</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>K2I13DR72L</RegistryNumber>
<NameOfSubstance>Gadolinium DTPA</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber>
<NameOfSubstance>Octreotide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>U194AS08HZ</RegistryNumber>
<NameOfSubstance>Edotreotide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Contrast Media</DescriptorName>
<QualifierName MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Gadolinium DTPA</DescriptorName>
<QualifierName MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Iopamidol</DescriptorName>
<QualifierName MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName>
<QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName>
<QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Reproducibility of Results</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Statistics as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year>
<Month>9</Month>
<Day>4</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2011</Year>
<Month>11</Month>
<Day>4</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2011</Year>
<Month>11</Month>
<Day>5</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year>
<Month>1</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>1</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>1</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>1</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pii">S0720-048X(11)00783-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.ejrad.2011.11.007</ArticleId>
<ArticleId IdType="pubmed">22236704</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV2/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F38 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F38 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22236704
   |texte=   Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22236704" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a IndiumV2

This area was generated with Dilib version V0.5.76.
Data generation: Tue May 20 07:24:43 2014. Site generation: Thu Mar 7 11:12:53 2024

	Serveur d'exploration sur l'Indium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'Indium

Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.

Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki